320 related articles for article (PubMed ID: 33347775)
1. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder.
Wymer KM; Sharma V; Saigal CS; Chamie K; Litwin MS; Packiam VT; Mossanen M; Pagliaro LC; Borah BJ; Boorjian SA
J Urol; 2021 May; 205(5):1326-1335. PubMed ID: 33347775
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
[TBL] [Abstract][Full Text] [Related]
5. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer.
Joshi M; Atlas SJ; Beinfeld M; Chapman RH; Rind DM; Pearson SD; Touchette DR
Value Health; 2023 Jun; 26(6):823-832. PubMed ID: 36529422
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.
Kulkarni GS; Alibhai SM; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Bayoumi AM
Cancer; 2009 Dec; 115(23):5450-9. PubMed ID: 19685529
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder Cancer.
Sharma V; Wymer KM; Borah BJ; Saigal CS; Litwin MS; Packiam VT; Thompson RH; Tollefson MK; Karnes RJ; Boorjian SA
J Urol; 2020 Sep; 204(3):442-449. PubMed ID: 32191580
[TBL] [Abstract][Full Text] [Related]
9. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
10. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
11. Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Matsumura Y; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
Int J Urol; 2022 Mar; 29(3):242-249. PubMed ID: 34902876
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R
Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
15. Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
Bukavina L; Bell S; Packiam VT; Smaldone M; Abbosh P; Uzzo R; Kutikov A; Correa AF; Magee DE
Urol Oncol; 2023 Sep; 41(9):391.e1-391.e4. PubMed ID: 37127478
[TBL] [Abstract][Full Text] [Related]
16. FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
Wright KM
Oncology (Williston Park); 2020 Feb; 34(2):44. PubMed ID: 32645193
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy.
Huelster HL; Mason NT; Davaro F; Naqvi SMH; Kim Y; Gilbert SM
Urology; 2024 May; 187():106-113. PubMed ID: 38467285
[TBL] [Abstract][Full Text] [Related]
19. A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.
Syed S; Rahman M; Israr A; Anwar M; Khatroth S; Safi D; Kamran A
SAGE Open Med; 2023; 11():20503121231160408. PubMed ID: 36949824
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
